SOURCE: Molecular Biometrics

October 10, 2007 12:30 ET

Metabolomic Profiling to Identify Embryos With Highest Reproductive Potential the Subject of Increased Attention at the 63rd ASRM Meeting

Molecular Biometrics' Biospectroscopy-Based Metabolomics Platform Featured in 5 IVF Clinical Studies

WASHINGTON, DC and CHESTER, NJ--(Marketwire - October 10, 2007) - Molecular Biometrics, a privately held metabolomics company, today announced that researchers will make 3 podium and 2 poster presentations detailing human clinical studies using the company's lead product candidate, ViaTest™-E, at the 63rd Annual Meeting of the American Society of Reproductive Medicine (ASRM) in Washington, DC, October 13 - 17, 2007. ViaTest-E is a non-invasive, point-of-care system that is being developed by Molecular Biometrics to help embryologists accurately identify viable embryos for transfer during in vitro fertilization (IVF) procedures.

James Posillico, Ph.D., President and CEO of Molecular Biometrics commented, "Given the high incidence of multiple gestation associated with IVF, many physicians are increasingly calling for a reduction in the number of embryos transferred and the movement to single embryo transfer (SET) as the standard of care in clinical practice. Molecular Biometrics is building a solid case for the use of metabolomic profiling to accurately identify viable embryos with the highest reproductive potential for transfer in IVF. Our goal is to offer IVF practitioners the tools they need to help make SET a reliable, routine practice in IVF."

Molecular Biometrics' presentations at ASRM include:

In a podium presentation (O-10: Room 143C: Reproductive Biologists Professional Group), Principal Investigator Zsolt Peter Nagy, M.D., Ph.D., (et. al.), will present findings of a study titled, Unique Biomarkers of Human Oocyte Maturation Assessed by Non-Invasive Metabolomic Profiling. This presentation will take place Monday, October 15, 2007 at 3:30 PM.

In a podium presentation (O-83: Room 152AB: Outcomes Predictions Laboratory: ART Abstracts), Principal Investigator Michael Tucker, Ph.D., (et. al.), will present findings of a study titled, Novel Approach to Viability Testing by Non-Invasive Metabolomic Profiling (METPRO) of Biomarkers of Oxidative Metabolism (OM) from Blastocysts Used for Single Embryo Transfer (SET). This presentation will take place Monday, October 15, 2007 at 4:15 PM.

In a podium presentation (O-73: Room 207B: Other: ART Abstracts), Principal Investigator O. Kato, (et. al.), will present findings of a study titled, Metabolomic Assessment of Day 2 (D2) Embryos Based on Pregnancy Outcome after Single Embryo Transfer (SET). This presentation will take place Monday, October 15, 2007 at 3:45 PM.

In a poster presentation (# P-660: Hall E, Washington Convention Center), Principal Investigator C.G. Vergouw, (et. al.), will present findings of a study titled, Non-Invasive Method for Embryo Selection in Single Embryo Transfer (SET) Using Metabolomic Profiling (METPRO) of Oxidative Metabolism (OM). This poster will be presented between 5:30 PM - 7:00 PM on Tuesday, October 16, 2007.

In a poster presentation (# P-605: Hall E, Washington Convention Center), Principal Investigator Thorir Hardarson, Ph.D., (et. al.), will present findings of a study titled, Non-Invasive Assessment of Embryo Reproductive Potential: Metabolomic Profiling of Biomarkers of Oxidative Metabolism (OM) During Embryo Development. This poster will be presented between 5:30 PM - 7:00 PM on Tuesday, October 16, 2007.

Metabolomics Background

Metabolomics is the systematic study of the unique biomarkers, or 'chemical fingerprints,' that processes of cellular metabolism leave behind, specifically, the study of their small-molecule metabolite profiles. Oxidative metabolism (OM), an intracellular process often referred to as cellular respiration, is known to affect the quality of spermatozoa, eggs and embryos. Complex interactions between pro-oxidants and antioxidants are crucial in the maintenance of normal intracellular homeostasis and this balance is closely related to OM. Molecular Biometrics uses biospectroscopy-based metabolomics to rapidly identify and simultaneously analyze multiple small molecule biomarkers of OM in IVF culture media. The unique metabolomic profiles of these biomarkers are analyzed by bioinformatics to yield new information about embryo quality.

For more information about ASRM visit http://www.asrm.org

About Molecular Biometrics

Based in Chester, New Jersey, with a research and development facility in Montreal, Quebec, Molecular Biometrics, LLC is a privately held metabolomics company developing highly specific and sensitive analytical methodologies for molecular diagnostic and monitoring applications in medicine, and for drug discovery and development through pharmacodiagnostics based on its novel technology platform of metabolomics. For more information, please visit http://www.molecularbiometrics.com/

Contact Information

  • Contact:
    Bryan P. Murphy
    LaVoie Group
    978.745.4200 x 105
    Email Contact